https://orcid.org/0000-0003-4602-6487
References
- Vogler S, Habl C, Bogut M, et al. Comparing pharmaceutical pricing and reimbursement policies in Croatia to the European Union Member States. Croat Med J. 2011;52(2):183–9.
- Fens T, van der Pol S, Kocks JWH, et al. Economic impact of reducing inappropriate inhaled corticosteroids use in patients with chronic obstructive pulmonary disease: ISPOR’s guidance on budget impact in practice. Value Heal. 2019;22(10):1092–1101.
- Vondeling GT, Cao Q, Postma MJ, et al. The impact of patent expiry on drug prices: a systematic literature review. Appl Health Econ Health Policy. 2018;16(5):653–660.
- Z-index. G-Standaard databank. https://www.z-index.nl/g-standaard.
- Axon. Close-UP national sales database. Available from: https://www.close-up-online.nl/close-up/Logon.aspx?ReturnUrl=%2Fclose-up%2FDefault.aspx.
- OPG group n.v. Press release preference policy causes extreme price decline. 2008. https://www.afm.nl/downloadregisterfile.aspx?type=openbaarmaking-voorwetenschap&enc=7Rpj0BBaMD5lzfwUlyQ9TIe+XbKYS1JE7+GVfXY2PxNqAT3NVNKp3QCQcI2WUb5gS/PYmhvg5EA+E7FpgiengZj0NLAMUDbP/oPnUtKH27VA0/CZGu7E4hLGdYYwwWpdhBL08ujGS087vBs9s/swrPvInrNxipZU6u/SvcVoaoQe+UGBFWjFGKmjOfq3TbL9KqxrE8GZ1uNd6BSBgSdTr/r7op8zwc/cJUTo87J0LQMsgmtRbb2oTKuoptZpNr0//uK8W4ohbMnr1dvbzx6yl5hVzFfiM/38JZkNenrJbQBPYiveQkQYIsm+5sUrEDIUy2+YYhNalosoIo7UR2EAMF17Bw8bj8WFsS1P0OqOfhQ=OPG Group N.V. Press release: Preference policy causes extreme price decline. 2008.
- Carp M, Kraal A, de Bekker P, et al. Management summary: effects of the preference policy for pharmaceuticals on the availability of medicines. 2018. https://www.berenschot.nl/publish/pages/6054/effects_preference_policy-berenschot.pdf
- Zorinstituut Nederland. Geneesmiddelen horizonscan. Published 2017. Available from: https://www.horizonscangeneesmiddelen.nl/binaries/content/assets/horizonscan/gepublicatie-scan-1-september-2017-correctie.pdf.
- Morgan SG, Vogler S, Wagner AK. Payers’ experiences with confidential pharmaceutical price discounts: A survey of public and statutory health systems in North America, Europe, and Australasia. Health Policy (New York). 2017;121(4):354–362.
- Kengetallen SF. Steeds meer geneesmiddelen onder de WGP. Pharm Weekbl. 2010;145(46–47):11.